Jacobs Levy Equity Management Inc. Has $4.35 Million Stock Holdings in OraSure Technologies, Inc. $OSUR

Key Points

• Jacobs Levy Equity Management Inc. increased its stake in OraSure Technologies by 39.3%, now owning 1,290,554 shares valued at approximately $4,349,000.
• Other institutional investors, including Tower Research Capital and Raymond James Financial, have also recently modified their holdings, leading to a total of 93.50% institutional ownership in the company.
• OraSure Technologies' stock has seen analysts’ ratings generally hold steady, with a consensus target price of $3.00 and a current trading price around $3.25.

Jacobs Levy Equity Management Inc. raised its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 39.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,290,554 shares of the medical instruments supplier's stock after acquiring an additional 363,946 shares during the period. Jacobs Levy Equity Management Inc. owned approximately 1.73% of OraSure Technologies worth $4,349,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its position in shares of OraSure Technologies by 202.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 5,234 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of OraSure Technologies in the fourth quarter valued at approximately $37,000. Gotham Asset Management LLC acquired a new stake in shares of OraSure Technologies in the fourth quarter worth $43,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in OraSure Technologies during the first quarter worth $49,000. Finally, Amundi bought a new position in OraSure Technologies during the first quarter worth $47,000. 93.50% of the stock is owned by institutional investors and hedge funds.

OraSure Technologies Stock Down 0.3%

OSUR traded down $0.01 during trading on Friday, reaching $3.31. 274,664 shares of the company's stock were exchanged, compared to its average volume of 570,469. The company has a market capitalization of $242.08 million, a P/E ratio of -4.94 and a beta of 0.44. The business has a 50 day moving average price of $3.12 and a 200 day moving average price of $3.06. OraSure Technologies, Inc. has a fifty-two week low of $2.36 and a fifty-two week high of $4.60.

Analyst Upgrades and Downgrades

OSUR has been the subject of a number of research reports. Evercore ISI reissued an "in-line" rating and issued a $3.00 price target on shares of OraSure Technologies in a report on Monday, May 19th. Wall Street Zen raised shares of OraSure Technologies from a "sell" rating to a "hold" rating in a research report on Saturday, May 17th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, OraSure Technologies currently has an average rating of "Hold" and an average target price of $3.00.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.